Cancer screening programs: who they are for, how often, and what a positive result means

Not every cancer can be screened for. As France’s National Cancer Institute (INCa) explains, a screening program needs a disease that is common, causes significant mortality and can be detected at a treatable stage; a test that performs well; and effective treatment. Age and risk level then decide who is offered the test. More testing is not automatically better.

Every test has limits. A false positive flags an abnormality that is not confirmed; a false negative misses one. Screening can also find cancers that would never have progressed, or only slowly: overdiagnosis. For breast cancer, INCa puts this at 10 to 20% of the cancers detected, with no way yet to tell them apart from those that will progress. This is why the Council of the European Union asks that benefits and risks, including overdiagnosis and overtreatment, be explained to participants in a way they can understand.

Within prevention as a whole, screening belongs to secondary prevention: finding a disease early, where primary prevention tries to stop it from occurring at all. What separates screening from a diagnostic test is covered in our guide to the preventive health check-up.

Unexplained or lasting pain, blood in the stool, unexplained vaginal bleeding, a persistent cough, an unusual change in a breast, a new mole or one that changes: these are among the warning signs listed by INCa. They do not necessarily mean cancer, but they are a reason to see a doctor, even if your screening is up to date. The age of your next invitation is never a reason to wait: with a symptom, the doctor orders diagnostic tests, outside the program’s schedule.

Waiting with a doubt is hard. Cindy, 34, noticed a mole changing and could not find a dermatologist with an opening for five months. Her story describes the need: knowing quickly whether it is urgent, without being left alone with the question.

In 2022, the Council Recommendation on cancer screening asked EU countries to offer screening through systematic, population-based programs with quality assurance. It sets out:

• breast cancer: mammography for women aged 50 to 69, with a suggested range of 45 to 74;
• cervical cancer: HPV testing for women aged 30 to 65, at an interval of five years or more;
• colorectal cancer: a quantitative fecal immunochemical test (FIT) between 50 and 74, leading to a colonoscopy when positive;
• lung cancer: low-dose CT, which countries should first explore through feasibility studies, starting with people at high risk.

Within this frame, each country sets its own ages, tests and intervals. Check the program where you live: the French figures below are an example, not a universal rule.

In France, invitations to the three national programs have been sent by the national health insurance since January 1, 2024. Within the programs, the screening test or its analysis is fully covered, with nothing to pay upfront; any consultation is reimbursed on the usual terms.

The French program is for women aged 50 to 74 with no symptoms and no particular risk factor other than age, according to the national health insurance (Assurance Maladie). Every two years, an invitation by letter, email or text message offers a mammogram with an accredited radiologist, along with a clinical breast exam: looking and feeling for abnormalities a mammogram does not always show.

The radiologist gives an initial result straight after the exam. If the images and the clinical exam show nothing abnormal, a second radiologist reads the mammogram again; final results are available within two weeks. If you have previous mammograms, bring them: the radiologist can compare.

Some situations call for different follow-up, agreed with a doctor: a personal history of breast cancer, atypical breast lesions, high-dose chest radiation before age 30, a family history or a genetic predisposition.

A normal mammogram says nothing about the future. A cancer can appear between two screenings; this is rare, fewer than 2 in 1,000 women screened according to INCa, but any unusual change in a breast between two exams should be reported to a doctor.

Between 50 and 74, women and men are invited every two years to take a fecal immunochemical test, which looks for blood in the stool that cannot be seen with the naked eye. The kit is available from a pharmacist, from a doctor or nurse during a consultation, or online; a few questions about your history first check that the test is right for you. You collect the sample at home and mail it to the laboratory in the envelope provided. The test and its analysis are fully covered.

A negative result (96% of cases) means no bleeding was detected at the time of the test. It does not rule everything out: some polyps and cancers do not bleed. A positive result (4% of cases) does not mean cancer, only that blood was found. A colonoscopy looks for the cause and can remove polyps before they progress; in more than half of cases, it finds no abnormality.

A personal or family history of polyps or colorectal cancer, or an inflammatory bowel disease (Crohn’s disease, ulcerative colitis), calls for specific follow-up decided with a doctor; the standard test does not replace it. And unusual, persistent abdominal pain or changes in bowel habits, or blood in the stool, are a reason to see a doctor, even after a negative test.

Screening is recommended for all women aged 25 to 65, whether or not they are vaccinated against HPV, including after menopause. From 25 to 29, it relies on cytology: two tests a year apart, then one every three years if the first two are normal. From 30, the high-risk HPV test takes over, three years after the last normal cytology, or straight away at 30 if there has been no previous screening, then every five years as long as it is negative.

Why the switch? Before 30, transient HPV infections are very common, and testing for them would lead to unnecessary tests and treatment. Screening more often than recommended is no more effective and increases false alarms. Only women who are not up to date receive an invitation; with it, the analysis is fully covered and the consultation where the sample is taken is reimbursed at 70%.

Vaccination protects against most of the HPV types that cause this cancer, but not all of them: it complements screening, it does not replace it. A total hysterectomy unrelated to cervical cancer ends screening. HIV infection, an organ transplant or exposure to diethylstilbestrol (DES) in the womb, on the other hand, call for a closer schedule set by a doctor.

A positive HPV test is not a cancer diagnosis. It shows a high-risk virus is present; the same sample is then checked for abnormal cells. If the infection comes with abnormal cells, a colposcopy, possibly with a biopsy, confirms or rules out a lesion.

France does not yet have a national lung cancer screening program. In 2022, the French National Authority for Health (HAS) recommended starting a pilot: in people at high risk, low-dose chest CT reduces deaths from this cancer, a benefit to weigh against false positives and overdiagnosis. The pilot, called Impulsion, was launched in May 2026 as an experiment in five regions: Auvergne-Rhône-Alpes, Hauts-de-France, Île-de-France, Pays de la Loire and Provence-Alpes-Côte d’Azur.

It is open to people aged 50 to 74 who smoke, or who quit less than 15 years ago, and who smoked on average at least one pack a day for 20 years or two packs a day for 10 years. The pathway combines two low-dose CT scans a year apart, then one every two years, with stop-smoking consultations, and it is fully covered. A positive scan leads to further tests before any conclusion is drawn. It is not screening for everyone: the criteria target the people who stand to benefit most.

A persistent cough, coughing up blood or breathlessness are among the warning signs: they call for medical advice, whether or not you meet the program’s criteria.

In a screening program, “positive” means the test justifies looking further, not that the disease is there. The confirmation step depends on the program: further imaging, sometimes a biopsy, for the breast; a colonoscopy for the bowel; a check for abnormal cells, then a colposcopy, for the cervix; further tests for the lung. For breast screening, the most common outcome of these tests is no cancer.

Follow the timeline and pathway you are given. If an appointment is slow to come or the next step is unclear, contact the doctor who follows you, your health insurer or, in France, the regional cancer screening coordination center (CRCDC).

With one program every two years, another every five, and tests done for symptoms in between, memory is not enough. For each test, keep four pieces of information:

• the exact name of the test and the program it belongs to;
• the date and place it was done;
• the full report, not just “normal” or “abnormal”;
• the next step you were given, and when.

This timeline avoids mixing up a screening test with one done for a symptom, and makes the next step clear to every professional. Our method for organizing a personal health record helps you file these reports. Also make sure your contact details are up to date with the organization that sends the invitations.

At an appointment, bring previous reports and mention any family history of cancer, ideally with the relationship and the age at diagnosis. Our guide on how to prepare for a doctor’s appointment covers the rest.

With MyTwin for patients, you build your medical record in a single app: lab results, imaging, reports. Your screening reports sit alongside the rest of your history. Choosing the tests and interpreting them remain the job of the professional who follows you.